602 related articles for article (PubMed ID: 22909827)
21. Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.
Schneider DJ
Coron Artery Dis; 2016 Jan; 27(1):65-9. PubMed ID: 26444255
[TBL] [Abstract][Full Text] [Related]
22. Thienopyridines and other ADP-receptor antagonists.
Bernlochner I; Sibbing D
Handb Exp Pharmacol; 2012; (210):165-98. PubMed ID: 22918731
[TBL] [Abstract][Full Text] [Related]
23. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
[TBL] [Abstract][Full Text] [Related]
24. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
[TBL] [Abstract][Full Text] [Related]
25. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
26. [Myocardial infarction: Role of new antiplatelet agents].
Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
Angiolillo DJ; Schneider DJ; Bhatt DL; French WJ; Price MJ; Saucedo JF; Shaburishvili T; Huber K; Prats J; Liu T; Harrington RA; Becker RC
J Thromb Thrombolysis; 2012 Jul; 34(1):44-55. PubMed ID: 22569899
[TBL] [Abstract][Full Text] [Related]
28. Platelet P2 receptors: old and new targets for antithrombotic drugs.
Cattaneo M
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
[TBL] [Abstract][Full Text] [Related]
29. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.
Grzesk G; Kozinski M; Navarese EP; Krzyzanowski M; Grzesk E; Kubica A; Siller-Matula JM; Castriota F; Kubica J
Thromb Res; 2012 Jul; 130(1):65-9. PubMed ID: 22265722
[TBL] [Abstract][Full Text] [Related]
30. Effect of P2Y
Spinthakis N; Farag M; Gue YX; Srinivasan M; Wellsted DM; Gorog DA
Thromb Res; 2019 Jan; 173():102-108. PubMed ID: 30500673
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
Husted SE; Storey RF; Bliden K; Tantry US; Høimark L; Butler K; Wei C; Teng R; Gurbel PA
Clin Pharmacokinet; 2012 Jun; 51(6):397-409. PubMed ID: 22515556
[TBL] [Abstract][Full Text] [Related]
32. P2Y receptor antagonists in thrombosis.
Boeynaems JM; van Giezen H; Savi P; Herbert JM
Curr Opin Investig Drugs; 2005 Mar; 6(3):275-82. PubMed ID: 15816504
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.
Jeong YH; Bliden KP; Antonino MJ; Park KS; Tantry US; Gurbel PA
Am Heart J; 2012 Jul; 164(1):35-42. PubMed ID: 22795280
[TBL] [Abstract][Full Text] [Related]
34. Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects.
Teng R; Carlson GF; Nylander S; Andersson TL
J Thromb Haemost; 2016 Dec; 14(12):2342-2352. PubMed ID: 27653814
[TBL] [Abstract][Full Text] [Related]
35. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Scharbert G; Wetzel L; Schrottmaier WC; Kral JB; Weber T; Assinger A
Transfusion; 2015 Jun; 55(6):1320-6. PubMed ID: 25641006
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
Anderson SD; Shah NK; Yim J; Epstein BJ
Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
[TBL] [Abstract][Full Text] [Related]
38. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Gurbel PA; Bliden KP; Butler K; Antonino MJ; Wei C; Teng R; Rasmussen L; Storey RF; Nielsen T; Eikelboom JW; Sabe-Affaki G; Husted S; Kereiakes DJ; Henderson D; Patel DV; Tantry US
Circulation; 2010 Mar; 121(10):1188-99. PubMed ID: 20194878
[TBL] [Abstract][Full Text] [Related]
39. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Floyd CN; Passacquale G; Ferro A
Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
[TBL] [Abstract][Full Text] [Related]
40. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin.
Fox SC; May JA; Shah A; Neubert U; Heptinstall S
Platelets; 2009 Jun; 20(4):250-9. PubMed ID: 19440925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
